Keywords: Javelin Pharmaceuticals, Ereska, orthopedic surgery

Javelin’s Ereska fails to meet key endpoints

Article | 11 August 2009

USA-based Javelin Pharmaceuticals saw its share price plummet almost 30% to $1.45, after the company revealed that one of its investigational drugs ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in